What happened with KIDS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
OrthoPediatrics supplies hospitals with products designed for children who need treatment for fractures, bone deformities and spinal curvature. Trauma and deformity correction brings in most revenue, followed by scoliosis care, and the United States is its main market. Hospitals generally hold its surgical implants and instruments on consignment, with implant sales tied to their use in surgery. Overseas, the company also sells to distributors that handle hospital billing and support surgeons.
The company also sells specialized braces and operates U.S. clinics that fit patients with custom braces and other orthotic and prosthetic products. These clinics receive payment mainly from commercial insurers, Medicare and Medicaid, as well as patients paying privately.
Sales depend on surgeons choosing its products, hospitals approving their use and pediatric procedures taking place. U.S. independent sales agencies generate most revenue, with two agencies contributing a meaningful share, so their hospital access and clinical support matter. New devices, significant modifications and new uses generally require regulatory clearance or approval before marketing; sales abroad also require authorization in each market.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
OrthoPediatrics’ results hinge on pediatric orthopedic procedure volumes and uptake of its implants and braces; Hanger clinics are also important to watch as a competitor in orthotic care.
Orthofix competes with OrthoPediatrics for surgeons’ and hospitals’ purchases of limb-reconstruction fixation products and spinal implants. Watch its Global Limb Reconstruction sales for the closest overlap with OrthoPediatrics’ trauma and deformity business, which supplied 70% of global revenue in 2025.
Globus Medical competes with OrthoPediatrics in implants and systems that guide surgeons during spinal-deformity and limb-reconstruction procedures. Its implant and surgical-navigation developments are more relevant to OrthoPediatrics than its wider portfolio, particularly alongside OrthoPediatrics’ exclusive pediatric distribution rights for the 7D Surgical FLASH navigation platform.
Enovis competes with OrthoPediatrics for overlapping medical customers buying orthopedic braces and limb-reconstruction implants. Watch bracing in its Prevention & Recovery business and limb reconstruction in Reconstructive, rather than treating all Enovis sales as a read-through to OrthoPediatrics.
Smith & Nephew competes with OrthoPediatrics for surgeons’ and hospitals’ purchases of orthopedic fixation and sports-medicine products. Product launches in those areas matter more for OrthoPediatrics than Smith & Nephew’s broader medical-technology sales.
Medtronic competes with OrthoPediatrics in spinal implants and technologies that help spine surgeons perform procedures. Watch its spine-product introductions alongside OrthoPediatrics’ scoliosis business, which accounted for 28% of global revenue in 2025.
Johnson & Johnson competes with OrthoPediatrics through DePuy Synthes, which supplies orthopedic fixation products and spinal implants to the surgical market. Watch that business rather than the parent’s overall revenue, which also includes a broad prescription-medicine business.
Stryker competes with OrthoPediatrics to supply orthopedic fixation products for limb-reconstruction procedures, but its overall business is much broader. Its fixation-product news is more relevant than total sales: Orthopaedics accounted for only 38% of Stryker’s net sales in 2025.
Zimmer Biomet competes with OrthoPediatrics to sell trauma and extremity implants to orthopedic surgeons, although its business is predominantly broader adult orthopedics. Watch new trauma and extremity products for the overlap with OrthoPediatrics, rather than its entire reconstructive portfolio.
Alphatec competes with OrthoPediatrics to sell spinal fixation and deformity solutions to spine surgeons, while OrthoPediatrics focuses on children. Watch surgeons’ adoption of Alphatec’s deformity solutions, but its reported revenue does not separate those products from its wider spine portfolio.
OrthoPediatrics Corp. earningsThis company
OrthoPediatrics’ report will show whether growth in its pediatric implants and scoliosis business is keeping pace with the costs and cash demands of expansion.
Read trauma and deformity and scoliosis sales alongside gross margin and operating cash flow. Rising sales with margin holding and cash outflow narrowing would mean more procedures are spreading the cost of instrument sets and service; slower sales or wider cash outflow would mean expansion still costs more than growth is bringing in, leaving profitability further off.
Orthofix Medical Inc. earningsOFIX
Orthofix’s report on Global Limb Reconstruction will show whether demand for the fixation products it shares with OrthoPediatrics’ largest business is strengthening or weakening.
Watch Orthofix’s Global Limb Reconstruction sales, not its total revenue. Stronger sales would suggest demand for limb-reconstruction procedures and hospital purchasing is holding up—a supportive signal for the trauma and deformity business that makes up 70% of OrthoPediatrics’ revenue. Weaker sales would point to cooling demand or purchasing in that market.
